M.D. Sass Equity Income Plus Fund
|Average Annual Total Return as of 3/31/18|
|MDEIX Institutional Class
|MDEPX Investor Class
|CBOE S&P 500 BuyWrite Index (BXM)||-1.56%||-1.56%||6.95%||7.22%||7.81%|
MDEIX Institutional Gross Expense ratio: 1.09% Net Expense ratio: 0.75%*
MDEPX Investor Gross Expense ratio: 1.44% Net Expense ratio: 1.10%*
*The Adviser has agreed to waive its management fees and/or reimburse Fund expenses to ensure that Total Annual Fund Operating Expenses (exclusive of interest, acquired fund fees and expenses, leverage and tax expenses, brokerage commissions, and extraordinary expenses) do not exceed 0.75% and 1.10% of the Fund's average daily net assets for the Institutional Class, Investor and Class shares, respectively, through at least September 28, 2018.
As of February 29, 2016, the Fund converted its Class C shares into Retail Class shares of the Fund and the Retail Class shares will be renamed Investor Class shares. As of January 28, 2016, the Fund's maximum sales charge imposed on purchases of Retail Class shares has been eliminated.
Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance of the Fund may be lower or higher than the performance quoted. Fund performance current to the most recent month-end may be lower or higher than the performance quoted and can be obtained by calling 1-855-637-3863.
MDEIX 2-Star Overall Morningstar Rating™ as of 12/31/17 out of 82 Option Writing Funds.
The Overall Morningstar Rating™ for a fund is derived from a weighted average of the fund's three-year Morningstar Rating™ metrics, which are based on risk-adjusted return performance.
For each fund with at least a three-year history, Morningstar calculates a Morningstar Rating (based on a Morningstar risk-adjusted return measure that accounts for variation in a fund's monthly performance, including the effects of sales charges, loads, and redemption fees), placing more emphasis on downward variations and rewarding consistent performance. The top 10% of funds in each category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars and the bottom 10% receive 1 star. As of 12/31/17, the MD Sass Short Term US Government Agency Income Fund was rated 3-Stars and 4-Stars against the following numbers of Short Government funds over the following time periods: 100 funds in the last three- and 91 funds in the last five-years. The M.D. Sass Equity Income Plus Fund (Institutional Class) was rated 2-Stars against the following numbers of Option Writing Funds over the following time periods: 82 funds in the last three years.
Investment performance reflects fee waivers in effect. In the absence of such waivers, total return would be reduced.
CBOE S&P 500 BuyWrite Index (BXM) is a benchmark index designed to track the performance of a hypothetical buy-write strategy on the S&P 500 Index. It is not possible to invest directly in an unmanaged index.